Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Glycemic Gap and 90-Day Mortality in Community-acquired Pneumonia: A Prospective Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. New Tobacco Products Do Not Protect Public Health

    Research output: Contribution to journalReviewResearchpeer-review

  3. Multiple Breath Washout for Diagnosing Asthma and Persistent Wheeze in Young Children

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Lower leptin/adiponectin ratio and risk of rapid lung function decline in chronic obstructive pulmonary disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Roger J Lewis
  • Derek C Angus
  • Pierre-François Laterre
  • Anne Louise Kjølbye
  • Egbert van der Meulen
  • Allan Blemings
  • Todd Graves
  • James A Russell
  • Jan E Carlsen
  • Karsten Jacobsen
  • Donald M Yealy
  • Steven M Opal
  • Nis A Windeløv
  • Bruno François
  • Anders Perner
  • Peter Pickkers
  • Scott M Berry
View graph of relations

Septic shock carries substantial morbidity and mortality. The failure of many promising therapies during late-phase clinical trials prompted calls for alternative trial designs. We describe an innovative trial evaluating selepressin, a novel selective vasopressin V1a receptor agonist, for adults with septic shock. SEPSIS-ACT (Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial) is a blinded, randomized, placebo-controlled, two-part, adaptive phase 2b/3 trial, evaluating up to four selepressin dosing strategies. The primary outcome is pressor- and ventilator-free days, with a value of zero assigned for death within 30 days. We calculate Bayesian probabilities of final trial success to guide interim decision-making. Part 1 (dose-finding) has an adaptive sample size based on response-adaptive randomization and prespecified rules to determine stopping for futility or selection of the best dosing regimen for Part 2. Part 2 (confirmation) randomizes a minimum of 1,000 patients equally to the selected dosing regimen or placebo. The final estimate of treatment effect compares all selepressin-treated patients with all placebo-treated patients. The sample size of 1,800 provides 91% power to detect an increase of 1.5 pressor- and ventilator-free days with a reduction in mortality of 1.5%. The trial received a Special Protocol Assessment agreement from the U.S. Food and Drug Administration Center for Drug Evaluation and Research and is underway in Europe and the United States. SEPSIS-ACT is an innovative trial that addresses both optimal dose and confirmation of benefit, accelerating the evaluation of selepressin while mitigating risks to patients and sponsor through use of response-adaptive randomization, a novel registration endpoint, prespecified futility stopping rules, and a large sample size. Clinical Trial registered with www.clinicaltrials.gov (NCT02508649).

Original languageEnglish
JournalAnnals of the American Thoracic Society
Volume15
Issue number2
Pages (from-to)250-257
Number of pages8
ISSN2325-6621
DOIs
Publication statusPublished - Feb 2018

ID: 55369543